Latest Trastuzumab Stories
Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP).
SAN DIEGO, July 28, 2011 /PRNewswire/ -- Biocept, Inc., an advanced diagnostic CLIA-certified service laboratory developing novel tests for the oncology community, today announced the availability of OncoCEE-BR(TM) for breast cancer, a test designed to detect circulating tumor cells (CTCs) found in the blood of patients with this disease, and to assess their HER2/neu status by fluorescence in situ hybridization (FISH) performed on the CTCs detected in the blood.
Patients with HER2-positive breast cancer may have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin.
Better Targeting of Pharmaceuticals to Patient's Genetic Profile Could Save $30B - $110B Annually WASHINGTON, July 25, 2011 /PRNewswire-USNewswire/ -- Genetic testing made possible by the mapping of the human genome can help the US cut costs and create jobs while at the same time improving survival rates for such diseases as cancer, HIV, and heart disease. This according to Alan Mertz, president of the American Clinical Laboratory Association (ACLA): "Genetic testing is going to be a powerful...
Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.
The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.
There may be new hope for patients with advanced breast cancer.
SAN DIEGO, July 15, 2011 /PRNewswire/ -- Biocept, Inc. announced today that it has appointed William G. Kachioff as Senior Vice President, Finance and Chief Financial Officer. As CFO, Mr.
Part of agency's efforts to promote development of personalized medicines and diagnostics SILVER SPRING, Md., July 12, 2011 /PRNewswire-USNewswire/ --The U.S.
Adding AfinitorÂ® to HerceptinÂ®, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies.
- Withering but not falling off, as a blossom that persists on a twig after flowering.